The development and validation of a novel virtual screening cascade protocol to identify potential serotonin 5-HT7R antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 8, 2010, Pages 2465-2468

  Kurczab, Rafał ^a   Nowak, Mateusz ^a   Chilmonczyk, Zdzisław ^b,c   Sylte, Ingebrigt ^d   Bojarski, Andrzej J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b National Medicine Institute   (Poland)

^c UNIVERSITY OF RZESZÓW   (Poland)

^d Medical Pharmacology and Toxicology   (Norway)

Author keywords

5 HT7 Receptors; Virtual screening

Indexed keywords

BENZODIOXAN DERIVATIVE; SEROTONIN 7 ANTAGONIST; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; PHYSICAL CHEMISTRY; VALIDATION STUDY;

MODELS, MOLECULAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 77950058867     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.012     Document Type: Article

References (28)

1. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena F.R., and Humphrey P.P.A. Pharmacol. Rev. 46 (1994) 157
2. Meyerhof W., Obermuller F., Fehr S., and Richter D.D.N.A. Cell Biol. 12 (1993) 401
3. Shen Y., Monsma F.J., Metcalf M.A., Jose P.A., Hamblin M.W., and Sibley D.R. J. Biol. Chem. 268 (1993) 18200
4. Bard J.A., Zgombick J., Adham N., Vaysse P., Branchek T.A., and Weinshank R.L. J. Biol. Chem. 268 (1993) 23422
5. Guscott M.R., Egan E., Cook G.P., Stanton J.A., Beer M.S., Rosahl T.W., Hartmann S., Kulagowski J., McAllister G., Fone K.C., and Hutson P.H. Neuropharmacology 44 (2003) 1031
6. Duncan M.J., and Davis V.A. Brain Res. 1058 (2005) 10
7. Meneses A. Behav. Brain Res. 155 (2004) 275
8. Leung E., Walsh L.K.M., Pulido-Rios M.T., and Eglen R.M. Br. J. Pharmacol. 117 (1996) 926
9. Mullins U.L., Gianutsos G., and Eison A.S. Neuropharmacology 21 (1999) 352
10. Ikeda M., Iwata N., Kitajima T., Suzuki T., and Yamanouchi Y. Neuropsychopharmacology 31 (2006) 866
11. Graf M., Jakus R., Kantor S., Levay G., and Bagdy G. Neurosci. Lett. 359 (2004) 45
12. Terron J.A. Eur. J. Pharmacol. 439 (2002) 1
13. Drogrul A., and Syrek M. Br. J. Pharmacol. 149 (2006) 498
14. Hedlund P.B. Psychopharmacology 206 (2009) 345
15. Varnek A., and Tropsha A. Chemoinformatics Approaches to Virtual Screening (2008), The Royal Society of Chemistry, Cambridge
16. Everes A., and Klebe G. J. Med. Chem. 47 (2004) 5381
17. Evers A., Hessler G., Matter H., and Klabunde T. J. Med. Chem. 48 (2005) 5448
18. Kellenberger E., Springael J.Y., Parmentier M., Hachet-Haas M., Galzi J.L., and Rognan D. J. Med. Chem. 50 (2007) 1294
19. Paillet-Loilier M., Fabis F., Lepailleur A., Bureau R., Butt-Gueulle S., Dauphin F., Delarue C., Vaudry H., and Rault S. Bioorg. Med. Chem. Lett. 15 (2005) 3753
20. Kołaczkowski M., Nowak M., Pawłowski M., and Bojarski A.J. J. Med. Chem. 49 (2006) 6732
21. Compounds were purchased from Enamine Ltd, Kiev, Ukraine, version 2008, http://www.enamine.net/.
22. Screen was used for generating pharmacophore descriptors and screening structures, JChem 5.0.3, 2008, ChemAxon, http://www.chemaxon.com.
23. Instant JChem was used for structure database management, search and various properties calculation, Instant JChem 2.3.1, 2008, ChemAxon, http://www.chemaxon.com.
24. van de Waterbeemd H., and Gifford E. Nat. Rev. 2 (2003) 192
25. Discovery Studio 2.5, Accelrys Inc., San Diego, CA, USA.
26. Schrödinger Suite 2008 Virtual Screening Workflow; Glide version 5.0, LigPrep version 2.2, Schrödinger, LLC, New York, NY, 2006.
27. Nowak M., Kołaczkowski M., Pawłowski M., and Bojarski A.J. J. Med. Chem. 49 (2006) 205
28. Dezi C., Brea J., Alvaro M., Ravina E., Masaguer C.F., Loza M.I., Sanz F., and Pastor M. J. Med. Chem. 50 (2007) 3242